INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Inotek Pharmaceuticals Corporation Invest...
January 10 2017 - 1:07PM
Business Wire
Law Offices of Howard G. Smith announces an investigation
on behalf of investors of Inotek Pharmaceuticals Corporation
(“Inotek” or the “Company”) (NASDAQ: ITEK) concerning the Company
and its officers’ potential violation of federal securities
laws.
Inotek is a clinical-stage biopharmaceutical company that
focuses on the discovery, development and commercialization of
therapies for glaucoma and other diseases of the eye in the United
States.
On January 3, 2017, Inotek revealed that its Phase 3 trial for
trabodenoson failed to reach its primary endpoint, despite prior
representations by the Company regarding the efficacy of the drug
and the likelihood of FDA approval. On this news, shares of Inotek
fell over 70% on January 3, 2017, closing at just $1.75 per
share.
If you purchased Inotek securities, have information or would
like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Howard G. Smith, Esquire,
of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by email
to howardsmith@howardsmithlaw.com, or visit our website at
www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170110006159/en/
Law Offices of Howard G. SmithHoward G. Smith,
Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Mar 2024 to Apr 2024
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Apr 2023 to Apr 2024